MNPR Monopar Therapeutics

Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

WILMETTE, Ill., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference. The Company’s presentation will be webcast beginning on Monday, September 11, 2023 at 7:00 a.m. ET. In person one-on-one meetings will take place at the Lotte New York Palace, NY, NY from September 11 - 13, 2023.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients. Monopar's pipeline consists of camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; MNPR-101, a late-stage preclinical antibody for radiopharmaceutical use in advanced cancers; and MNPR-202, an early-stage camsirubicin analog for various cancers. For more information, visit: .

CONTACT:  

Monopar Therapeutics Inc.

Investor Relations  

Kim R. Tsuchimoto  

Chief Financial Officer  

Follow Monopar on social media for updates: 

Twitter:   LinkedIn:



EN
05/09/2023

Underlying

MNPRMonopar Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Monopar Therapeutics

 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - T...

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025 WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that its abstract on the Phase 2 ALXN1840-WD-204 copper balance study has been selected for an oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025, taking place in Washington, D.C., from Nov...

October 15, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritt...

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 1,034,433 shares of its common stock at an offering price of $67.67 per share and, in lieu of shares of common stock to certain investors, pr...

September 24, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter t...

Monopar Announces Journal of Hepatology Publishes Physicians’ Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that the Journal of Hepatology has published a peer-reviewed Letter to the Editor (), authored by leading Wilson disease physicians, entitled “Oral Bis-choline Tetrathiomolybdat...

September 24, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar to Present New Long-Term Neurological Efficacy and Safety Data...

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 (tiomolybdate choline) for Wilson disease will be presented at the 150th A...

September 14, 2025 1 EN
 PRESS RELEASE
Free
MNPR Monopar Therape...

Monopar Announces Abstract Accepted with Distinction for Oral and Post...

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting WILMETTE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that its abstract on the long-term neurological benefits of ALXN1840 (tiomolybdate choline) in Wilson disease patients has been selected for both oral and poster presentation...

September 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch